Fennec Pharmaceuticals Inc. (FENC) — 8-K Filings

8-K Filings (18)

• Fennec Pharmaceuticals Files 8-K — Dec 9, 2025 Risk: low
  Fennec Pharmaceuticals Inc. filed an 8-K on December 9, 2025, reporting on other events and financial statements. The company, previously known as Adherex Techn
• 8-K Filing — Dec 2, 2025
• 8-K Filing — Nov 19, 2025
• 8-K Filing — Nov 18, 2025
• 8-K Filing — Nov 17, 2025
• Fennec Pharmaceuticals Files 8-K on Security Holder Vote — Jun 3, 2025 Risk: medium
  Fennec Pharmaceuticals Inc. filed an 8-K on June 3, 2025, reporting on a submission of matters to a vote of security holders. The company, previously known as A
• Fennec Pharmaceuticals Files 8-K on Financials — Mar 10, 2025 Risk: low
  Fennec Pharmaceuticals Inc. filed an 8-K on March 10, 2025, reporting on its results of operations and financial condition. The filing includes financial statem
• Fennec Pharmaceuticals Files 8-K — Feb 7, 2025 Risk: low
  Fennec Pharmaceuticals Inc. filed an 8-K on February 7, 2025, reporting other events and financial statements. The company, previously known as Adherex Technolo
• Fennec Pharmaceuticals Closes $3.02M Public Offering — Dec 20, 2024 Risk: medium
  Fennec Pharmaceuticals Inc. announced on December 18, 2024, the closing of its previously announced underwritten public offering of common stock. The offering r
• Fennec Pharmaceuticals Board Changes — Oct 30, 2024 Risk: medium
  Fennec Pharmaceuticals Inc. announced on October 28, 2024, a change in its board of directors. Dr. David M. Levinson has been appointed as the new Chairman of t
• Fennec Pharmaceuticals Board Shakeup — Aug 7, 2024 Risk: medium
  Fennec Pharmaceuticals Inc. announced on August 5, 2024, a change in its Board of Directors. Dr. David M. Levinson has been appointed as the new Chairman of the
• Fennec Pharmaceuticals Appoints New CMO and CSO — Jul 2, 2024 Risk: medium
  Fennec Pharmaceuticals Inc. announced on June 30, 2024, the appointment of Dr. Adrian J. Wildfire as Chief Medical Officer and Dr. Robert J. B. Davies as Chief
• Fennec Pharmaceuticals Files 8-K on Security Holder Votes — Jun 25, 2024 Risk: low
  Fennec Pharmaceuticals Inc. filed an 8-K on June 25, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specifi
• Fennec Pharmaceuticals to be Acquired by Halozyme Therapeutics — May 9, 2024 Risk: medium
  Fennec Pharmaceuticals Inc. announced on May 7, 2024, that it has entered into a definitive agreement to be acquired by Halozyme Therapeutics, Inc. for $10.00 p
• Fennec Pharmaceuticals Files 8-K on Financials — Mar 25, 2024 Risk: low
  Fennec Pharmaceuticals Inc. filed an 8-K on March 25, 2024, reporting results of operations and financial condition as of March 21, 2024. The filing details fin
• Fennec Pharmaceuticals Enters Material Definitive Agreement — Mar 21, 2024 Risk: medium
  Fennec Pharmaceuticals Inc. announced on March 15, 2024, that it has entered into a Material Definitive Agreement. The company also reported on other events and
• Fennec Pharma Files 8-K on Other Events and Financial Exhibits — Feb 29, 2024 Risk: low
  FENNEC PHARMACEUTICALS INC. filed an 8-K on February 29, 2024, reporting 'Other Events' and 'Financial Statements and Exhibits'. The filing indicates a current
• Fennec Pharma Confirms Nasdaq Listing for Common Shares — Feb 2, 2024
  Fennec Pharmaceuticals Inc. filed an 8-K on February 1, 2024, to update its registration for common shares on the Nasdaq Capital Market. This filing confirms th

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX